Skip to content

Study to Evaluate the Effect of Sorbion Sachet S Wound Dressing

Clinical Study of Evaluate the Effect of Sorbion Sachet S Wound Dressing on Soft Tissue Edema and Wound Bioburden in Moderately to Highly Exuding Pressure Ulcers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01319097
Enrollment
5
Registered
2011-03-21
Start date
2010-04-30
Completion date
2011-08-31
Last updated
2011-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pressure Ulcers

Keywords

Reduction on local soft tissue edema

Brief summary

This is a clinical study to evaluate the effects of sorbion sachet s wound dressing on soft tissue edema and wound bioburden in moderately to highly exuding pressure ulcers.

Detailed description

This study is aimed at the participation of subject with moderately to highly exuding pressure ulcers. Each Subject is expected to participate for a period of 4 weeks or until reepithelization, which occurs first.

Interventions

OTHERSorbion Sachet S

Dressing is indicated for moderately to heavily exuding wounds.

Sponsors

Sorbion Aktiengesellschaft, Germany
CollaboratorUNKNOWN
Southwest Regional Wound Care Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject \> 18 years. * Subject is attending SW Wound Care Center * Subject has a wound not smaller than 1cm2 * Subject has a wound not larger than 14cm X 23cm * Subject has a moderately to highly exudative pressure ulcer that would be indicated for treatment with sorbion sachet S * Subject or subject's legally authorized representative is informed about the trial, understands the nature of the study and provides written informed consent prior to study enrollment. * Subject is willing and able to comply with all specified care and visit requirements.

Exclusion criteria

* Subject has a lesion that does not meet the inclusion criteria. * Subject has a pressure ulcer that contains areas of undermined tissue. * Subject refuses to participate in the study. * Subject is participating in another clinical study. * Subject already participates in this study with one wound (only one wound per subject is allowed) * Subject has known sensitivity to the trial product or any of its compounds. * Subject is expected to be non-compliant. * Subject uses therapy known to be immunocompromising such as systemic anti cancer drugs and/or systemic corticosteroids. * Subject suffers from systemic infectious disease(s) known to negatively influence wound healing, such as AIDS. * Subject's lesion is a primary skin cancer. * Subject's lesion is the manifestation of a metastasis. * Subject is pregnant.

Design outcomes

Primary

MeasureTime frameDescription
The primary objective of this study is to investigate the effect of sachet S reduction on local soft tissue edema (excessive interstitial fluid to a maximum 3cm depth) in pressure ulcers.1 yearTo investigate the effect of sachet S reduction on local soft tissue edema in pressure ulcers and the degree to which sachet S influences the wound surface bioburden qualitatively and quantitatively.

Secondary

MeasureTime frameDescription
The secondary objectives are to further investigate whether sorbion sachet s1 yearGenerates changes in subjective parameters Generates changes in wound size Leads to clinician satisfaction and patient compliance with sachet s

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026